Hikma Intl Pharms patents expiration
1. Mitigare patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675613 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
| US8927607 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
| US9399036 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
| US9555029 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
| US9789108 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 26 September, 2014
Treatment: Method of using colchicine for the prophylaxis of gout flares
Dosage: CAPSULE;ORAL
How can I launch a generic of MITIGARE before it's drug patent expiration?
More Information on Dosage
MITIGARE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic